Atopic DermatitisPhase 2NCT07150845
Phase 2b Study of EVO756 in Adults With Atopic Dermatitis
A Phase 2 study testing EVO756 in people with Atopic Dermatitis, run by Evommune, Inc. at 29 sites in 2 countries.
Trial summary
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Atopic Dermatitis
- What is being tested?
- EVO756
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 121 participants
- Where
- 29 sitesin 2 countries
- Study dates
- 26 Aug 2025to 3 Aug 2026
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Chronic AD that has been present for ≥6 months
- Validated-Investigator's Global Assessment score of ≥3
- EASI of ≥16
- BSA of AD involvement of ≥10%
Who cannot join
- Any clinically significant abnormality in laboratory evaluations, physical examinations, vital signs, or ECG at Screening
- Use of certain medications
- Presence of skin comorbidities or other condition(s) that may interfere with study assessments
- Significant AD flare, in the opinion of the Investigator, within 4 weeks prior to study entry
Trial locations and contacts
29 sites in 2 countries.
29 sites in 2 countries
United States24 sites
Great Lakes Research Group, Inc.
Bay City, Michigan, 48706
Skin Care Research, LLC
Boca Raton, Florida, 33486
Equity Medical
Bowling Green, Kentucky, 42104
DOCS Dermatology Clinical Research
Canal Winchester, Ohio, 43110
DS Research
Clarksville, Indiana, 47129
Driven Research, LLC
Coral Gables, Florida, 33134
Empire Dermatology
East Syracuse, New York, 13057
Center for Dermatology Clinical Research
Fremont, California, 94538
Skin Care Research - Hollywood Dermatology
Hollywood, Florida, 33021
Stryde Research
Lewisville, Texas, 75056
Metropolis Dermatology - Downtown Los Angeles
Los Angeles, California, 90017
International Clinical Research - Murfreesboro
Murfreesboro, Tennessee, 37130
Equity Medical
New York, New York, 10023
Skin and Beauty Center
Pasadena, California, 91105
Saguaro Dermatology
Phoenix, Arizona, 85008
Skin Search of Rochester, Inc.
Rochester, New York, 14623
Aesthetic and Dermatology Center
Rockville, Maryland, 20850
MediSearch Clinical Trials
Saint Joseph, Missouri, 64507
Progressive Clinical Research
San Antonio, Texas, 78213
Jordan Valley Dermatology Center
South Jordan, Utah, 84095
TrueBlue Clinical Research
Tampa, Florida, 33609
Revival Research Institute, LLC
Troy, Michigan, 48084
Michigan Dermatology Institute
Waterford, Michigan, 48328
Wilmington Dermatology Center
Wilmington, North Carolina, 28405
New Zealand5 sites
Optimal Clinical Trials
Auckland, NZL, 1010
Optimal Clinical Trials
Auckland, NZL, 632
Pacific Clinical Research Network (PCRN) - Christchurch
Christchurch Central City, Christchurch, 8013
Clinical Trials NZ Limited
Hamilton, NZL, 3204
Momentum Clinical Research Lower Hutt
Lower Hutt, NZL, 5010
About this study
Official title: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults With Atopic Dermatitis
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.
- Conditions
- Atopic Dermatitis
- Being tested
- EVO756, Placebo control
- Keywords
- atopic dermatitis, eczema, itch
- Medical subject headings
- Dermatitis, Atopic, Eczema, Pruritus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EVO756Drug
Dose 1
EVO756Drug
Dose 2
EVO756Drug
Dose 3
Placebo controlDrug
Placebo control
| Study group | Role | What they receive |
|---|---|---|
| Dose 1 | Experimental | Orally administered EVO756, Dose 1 Receives: Drug: EVO756 |
| Dose 2 | Experimental | Orally administered EVO756, Dose 2 Receives: Drug: EVO756 |
| Dose 3 | Experimental | Orally administered EVO756, Dose 3 Receives: Drug: EVO756 |
| Placebo | Placebo comparator | Placebo control Receives: Drug: Placebo control |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage change in Eczema Area and Severity Index (EASI) from Baseline
Measured: Week 12
Secondary outcomes (9)
Percentage change in EASI from Baseline
Measured: Weeks 2, 4, and 8
Mean changes in EASI from Baseline
Measured: Week 2, 4, 8, and 12
Proportion of subjects with EASI-50, EASI-75, and EASI-90 from Baseline
Measured: Weeks 2, 4, 8, and 12
Mean and absolute changes in validated Investigator Global Assessment (vIGA) score from Baseline
Measured: Weeks 2, 4, 8, and 12
Proportion of subjects achieving a vIGA score of 0,1 with at least a 2-point reduction from Baseline
Measured: Weeks 2, 4, 8, and 12
Mean and percentage change from Baseline in the pruritus-NRS score
Measured: Weeks 2, 4, 8, and 12
Proportion of subjects achieving a 4-pt reduction in the pruritus-NRS score from Baseline
Measured: Week 2, 4, 8, and 12
Mean and percentage changes from Baseline in Body Surface Area (BSA) of affected area
Measured: Weeks 2, 4, 8, and 12
Occurrence of treatment emergent adverse events (TEAE) and serious adverse events (SAE)
Measured: through Week 14
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Sep 2025
- Study start26 Aug 2025
- Primary completion23 Jul 2026
- Study completion3 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atopic DermatitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 121 participants (actual)
Sponsor and investigators
- Lead sponsor
- Evommune, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07150845
- Sponsor's protocol ID
- EVO756-AD001
- Status last verified
- Sep 2026
- First submitted
- 28 Aug 2025
- Last updated
- 5 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults With Atopic Dermatitis
- ClinicalTrials.gov ID
- NCT07150845
- Acronym / sponsor ID
- EVO756-AD001
- Conditions
- Atopic Dermatitis
- Keywords
- atopic dermatitis, eczema, itch
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 121 participants (actual)
- Lead sponsor
- Evommune, Inc.Industry (pharma, biotech, devices)
- Study start
- 26 Aug 2025 (actual)
- Primary completion
- 23 Jul 2026 (actual)
- Study completion
- 3 Aug 2026 (actual)
- First posted
- 2 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Dose 1 | Experimental | Drug: EVO756Orally administered EVO756, Dose 1 |
| Dose 2 | Experimental | Drug: EVO756Orally administered EVO756, Dose 2 |
| Dose 3 | Experimental | Drug: EVO756Orally administered EVO756, Dose 3 |
| Placebo | Placebo comparator | Drug: Placebo controlPlacebo control |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Chronic AD that has been present for ≥6 months
- Validated-Investigator's Global Assessment score of ≥3
- EASI of ≥16
- BSA of AD involvement of ≥10%
Key exclusion criteria (4 listed)
- Any clinically significant abnormality in laboratory evaluations, physical examinations, vital signs, or ECG at Screening
- Use of certain medications
- Presence of skin comorbidities or other condition(s) that may interfere with study assessments
- Significant AD flare, in the opinion of the Investigator, within 4 weeks prior to study entry
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EVO756Dose 1 | Drug | Dose 1 |
| EVO756Dose 2 | Drug | Dose 2 |
| EVO756Dose 3 | Drug | Dose 3 |
| Placebo controlPlacebo control | Drug | Placebo |
Primary outcome
Percentage change in Eczema Area and Severity Index (EASI) from Baseline
Time frame: Week 12
9 secondary outcomes
Percentage change in EASI from Baseline
Time frame: Weeks 2, 4, and 8
Mean changes in EASI from Baseline
Time frame: Week 2, 4, 8, and 12
Proportion of subjects with EASI-50, EASI-75, and EASI-90 from Baseline
Time frame: Weeks 2, 4, 8, and 12
Mean and absolute changes in validated Investigator Global Assessment (vIGA) score from Baseline
Time frame: Weeks 2, 4, 8, and 12
Proportion of subjects achieving a vIGA score of 0,1 with at least a 2-point reduction from Baseline
Time frame: Weeks 2, 4, 8, and 12
Mean and percentage change from Baseline in the pruritus-NRS score
Time frame: Weeks 2, 4, 8, and 12
Proportion of subjects achieving a 4-pt reduction in the pruritus-NRS score from Baseline
Time frame: Week 2, 4, 8, and 12
Mean and percentage changes from Baseline in Body Surface Area (BSA) of affected area
Time frame: Weeks 2, 4, 8, and 12
Occurrence of treatment emergent adverse events (TEAE) and serious adverse events (SAE)
Time frame: through Week 14
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Atopic Dermatitis
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
RecruitingObservational study
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Cutaneous T-cell Lymphoma, Sezary Syndrome
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruitingPhase 1
A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic Dermatitis
Dermatitis Atopic
RecruitingPhase 3
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
29 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing EVO756 in people with Atopic Dermatitis, run by Evommune, Inc. at 29 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 29 sites in United States, New Zealand. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage change in Eczema Area and Severity Index (EASI) from Baseline (time frame: Week 12). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Oct 2026.